Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)

  1. Leineweber, C.G.
  2. Rabehl, M.
  3. Pietzner, A.
  4. Rohwer, N.
  5. Rothe, M.
  6. Pech, M.
  7. Sangro, B.
  8. Sharma, R.
  9. Verslype, C.
  10. Basu, B.
  11. Sengel, C.
  12. Ricke, J.
  13. Schebb, N.H.
  14. Weylandt, K.-H.
  15. Benckert, J.
Journal:
Frontiers in Pharmacology

ISSN: 1663-9812

Year of publication: 2023

Volume: 14

Type: Erratum

DOI: 10.3389/FPHAR.2023.1354581 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus